S. Karger AG

SHERPA: Unknown

People

  1. Abou-Alfa
    Abou-Alfa
  2. Janjigian
    Janjigian
  3. O'Reilly
    O'Reilly
  4. Ilson
    Ilson
  5. Saltz
    Saltz
  6. Cercek Hanjis
    Cercek Hanjis
  7. Molena
    Molena
  8. Raj
    Raj
  9. Bajorin
    Bajorin
  10. Bodei
    Bodei

Groups

  1. Department of Medicine (57)
  2. Gastrointestinal Oncology Service (57)
  3. Solid Tumor Oncology Division (57)
  4. Center for Pancreatic Cancer Research (15)
  5. Survivorship Research (5)
  6. Surgery (4)
  7. Weinberg Fellows (4)
  8. Graduate Medical Education (3)
  9. Biostatistics Service (2)
  10. Body Imaging Service (2)
Search Within
  1. "Gastrointestinal Oncology Service"
Formats
  1. Meeting Abstract (48)
  2. Journal Article (9)
Groups
  1. Department of Medicine (57)
  2. Gastrointestinal Oncology Service (57)
  3. Solid Tumor Oncology Division (57)
  4. Center for Pancreatic Cancer Research (15)
  5. Survivorship Research (5)
  6. Surgery (4)

More Groups

People
  1. Ghassan Abou-Alfa (18)
  2. Yelena Janjigian (12)
  3. Eileen O'Reilly (8)
  4. David Ilson (4)
  5. Diane Reidy (4)
  6. Andrea Cercek Hanjis (3)

More People

Years
  1. 2024 (7)
  2. 2023 (8)
  3. 2022 (6)
  4. 2021 (5)
  5. 2020 (10)
  6. 2019 (7)

More Years

Publications
  1. Oncology Research and Treatment (46)
  2. Neuroendocrinology (4)
  3. Oncology (4)
  4. Onkologie (2)
  5. Case Reports in Oncology (1)

Results (57)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Fight-202: A phase 2 study of pemigatinib in patients (PTS) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)
    Meeting Abstract

    Vogel, A.; Sahai, V.; Hollebecque, A.; Vaccaro, G.; Melisi, D.; Al-Rajabi, R.; Paulson, A. S.; Borad, M. J.; Gallinson, D.; Murphy, A. G.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • POLO: Efficacy and health-related quality of life (HRQOL) with maintenance olaparib following first-line platinum-based chemotherapy (PBC) in patients (PTS) with a germline BRCA mutation and metastatic pancreatic cancer (MPC)
    Meeting Abstract

    Reinacher-Schick, A. C.; Kindler, H. L.; Hammel, P.; Reni, M.; Van Cutsem, E.; Mercade, T. M.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Oh, D. Y.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • BEACON CRC: A randomized, phase 3 study of encorafenib (ENCO) and cetuximab (CETUX) with or without binimetinib (BiNI) vs. choice of either irinotecan or folfiri plus cetux in BRAF V600E-mutant metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Vogel, A.; Hegewisch-Becker, S.; Prager, G.; Folprecht, G.; Stahl, M.; Kopetz, S.; Grothey, A.; van Cutsetn, E.; Yaeger, R.; Wasan, H.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Association of adverse events (AES) with efficacy outcomes for cabozantinib (C) in patients (PTS) with advanced hepatocellular carcinoma (AHCC) in the phase 3 CELESTIAL trial
    Meeting Abstract

    Waidmann, O.; Abou-Alfa, G. K.; Meker, T.; Cheng, A. L.; Cicin, I.; Bolondi, L.; Klumpem, H. J.; Chan, S. L.; Dadduzio, V.; Milwee, S.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Quality-adjusted life years accrued with cabozantinib in patients with advanced hepatocellular carcinoma (AHCC) in the CELESTIAL trial
    Meeting Abstract

    Venerito, M.; Abou-Alfa, G. K.; Mollon, P.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Kelley, R. K.; Baron, A. D.; Benzaghou, F.; Valcheva, V.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison of cabozantinib (C) versus regorafenib (R) in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Venerito, M.; Kelley, R. K.; Mollon, P.; Blanc, J. F.; Daniele, B.; Yau, T.; Cheng, A. L.; Valcheva, V.; Remiro Azocar, A.; Baio, G.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric cancer (mGC) with or without prior gastrectomy: Results from a phase III study (TAGS)
    Meeting Abstract

    Thuss-Patience, P.; Lorenzen, S.; Ettrich, T.; Karthaus, M.; Ilson, D. H.; Prokharau, A.; Arkenau, H. T.; Ghidini, M.; Fujitani, K.; Van Cutsem, E.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Association of PD-L1 combined positive score (CPS) and immune gene signatures with efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC)
    Meeting Abstract

    Haag, G.; Lei, M.; Siemers, N.; Pandya, D.; Chang, H.; Sanchez, T.; Dorange, C.; Harbison, C.; Szabo, P.; Janjigian, Y.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Association of adverse events (AEs) with efficiacy outcomes for Cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase 3 CELESTIAL trial
    Meeting Abstract

    Trojan, J.; Abou-Alfa, G. K.; Meyer, T.; Cheng, A. L.; Cicin, I.; Bolondi, L.; Klümpen, H. J.; Chan, S. L.; Dadduzio, V.; Milwee, S.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Quality-adjusted life years accrued with cabozantinib in patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial
    Meeting Abstract

    Trojan, J.; Abou-Alfa, G. K.; Mollon, P.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Kelley, R. K.; Baron, A. D.; Benzaghou, F.; Valcheva, V.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save